F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML)
AML F18-FLT
1 other identifier
observational
10
1 country
1
Brief Summary
PET/CT is reliable tool in evaluation of treatment response in number cancers. F18-FLT is a precursor of DNA with high uptake in the bone marrow as a part of normal biodistribution. Highly increased uptake of this radiopharmaceutical was shown in a number of hematologic disease either in bone marrow or extramedullary. F18-FLT PET/CT can provide a tool for whole body assessment of activity in bone marrow as well as early estimation of treatment efficacy or lack of it. In addition, this noninvasive study can replace bone marrow biopsy and predict response vs. non response to therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 16, 2012
CompletedFirst Posted
Study publicly available on registry
May 7, 2012
CompletedStudy Start
First participant enrolled
October 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2013
CompletedMay 7, 2012
April 1, 2012
1 year
April 16, 2012
May 3, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Measure of extent and intensity ( by standardized uptake value - SUV) of disease in bone marrow demonstrated on PET/CT images before and after treatment.
Secondary Outcomes (1)
prediction of treatment response by dynamics of FLT uptake(by SUV)in comparison to bone marrow biopsy
Study Arms (1)
AML
patients with AML prior and after treatment
Eligibility Criteria
patients with new diagnosis of AML
You may qualify if:
- new diagnosis of AML
You may not qualify if:
- pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hadassah Hebrew University Medical Center
Jerusalem, Israel
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 16, 2012
First Posted
May 7, 2012
Study Start
October 1, 2012
Primary Completion
October 1, 2013
Last Updated
May 7, 2012
Record last verified: 2012-04